Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5TZT

Crystal structure of human CD47 ECD bound to Fab of C47B161

5TZT の概要
エントリーDOI10.2210/pdb5tzt/pdb
関連するPDBエントリー5TZ2 5TZU
分子名称Light Chain of Fab C47B161, Heavy Chain of Fab C47B161, Leukocyte surface antigen CD47, ... (6 entities in total)
機能のキーワードantigen-fab complex, immunoglobulin, immune system
由来する生物種Homo sapiens
詳細
タンパク質・核酸の鎖数6
化学式量合計127523.48
構造登録者
Cardoso, R.M.F. (登録日: 2016-11-22, 公開日: 2017-03-15, 最終更新日: 2024-11-06)
主引用文献Pietsch, E.C.,Dong, J.,Cardoso, R.,Zhang, X.,Chin, D.,Hawkins, R.,Dinh, T.,Zhou, M.,Strake, B.,Feng, P.H.,Rocca, M.,Santos, C.D.,Shan, X.,Danet-Desnoyers, G.,Shi, F.,Kaiser, E.,Millar, H.J.,Fenton, S.,Swanson, R.,Nemeth, J.A.,Attar, R.M.
Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies.
Blood Cancer J, 7:e536-e536, 2017
Cited by
PubMed Abstract: CD47, a broadly expressed cell surface protein, inhibits cell phagocytosis via interaction with phagocyte-expressed SIRPα. A variety of hematological malignancies demonstrate elevated CD47 expression, suggesting that CD47 may mediate immune escape. We discovered three unique CD47-SIRPα blocking anti-CD47 monoclonal antibodies (mAbs) with low nano-molar affinity to human and cynomolgus monkey CD47, and no hemagglutination and platelet aggregation activity. To characterize the anti-cancer activity elicited by blocking CD47, the mAbs were cloned into effector function silent and competent Fc backbones. Effector function competent mAbs demonstrated potent activity in vitro and in vivo, while effector function silent mAbs demonstrated minimal activity, indicating that blocking CD47 only leads to a therapeutic effect in the presence of Fc effector function. A non-human primate study revealed that the effector function competent mAb IgG1 C47B222-(CHO) decreased red blood cells (RBC), hematocrit and hemoglobin by >40% at 1 mg/kg, whereas the effector function silent mAb IgG2σ C47B222-(CHO) had minimal impact on RBC indices at 1 and 10 mg/kg. Taken together, our findings suggest that targeting CD47 is an attractive therapeutic anti-cancer approach. However, the anti-cancer activity observed with anti-CD47 mAbs is Fc effector dependent as are the side effects observed on RBC indices.
PubMed: 28234345
DOI: 10.1038/bcj.2017.7
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.89 Å)
構造検証レポート
Validation report summary of 5tzt
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon